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To date, most of the clinical cytotoxic anticancer drugs target all rapidly dividing 
cells and are non-selective in their mechanism of action by disrupting essential 
components that are crucial to both malignant and normal cells. Hence, the search for 
more effective and selective anticancer drugs is currently being researched actively 
involving the various entities of the drug discovery programme.  We at UPM have 
shown that andrographolide (AGP), a compound isolated from a local herb, 
Andrographis paniculata, to have anticancer activity in vitro and in vivo. In order to 
improve the antitumour properties of AGP, semi-synthetic derivatives of this 
compound were synthesised in our laboratory, with the aim of identifying the most 
promising anticancer compound among the AGP derivatives and to elucidate the 
mechanism(s) of action of the compound. The in vitro antitumour study showed that 
3,19-(2-bromobenzylidene)andrographolide (SR09) displayed better antitumour 
activity when compared with AGP and other derivatives namely 3,19-(2-
chlorobenzylidene)andrographolide (SRJ11) and 3,19-(3-chloro-4-
fluorobenzylidene) andrographolide (SRJ23). The antitumour activity of AGP, 
SRJ09, SRJ11 and SRJ23 was shown to be not compromised by P-glycoprotein 
activities in MES-SA Dx5 multidrug resistant cell line. The time-course study 
 iii
revealed SRJ09 had a rapid acting interval compared with AGP. SRJ09 was 
previously shown to induce G1-phase cell cycle arrest and in this study the effect 
was shown attributed to increased of p21 (CDK inhibitor) expression without 
affecting the expression of cyclin D1. Apoptosis was the main mode of cell death 
induced by SRJ09 and was p53 and bcl-2 independent, which might suggest that 
SRJ09 act through the extrinsic apoptotic pathway. A simple pharmacokinetic study 
was performed in Balb/c for the purpose of dose selection for in vivo study revealed 
that SRJ09 had a relatively short half-life but was able to reach in vitro cytotoxic 
concentration range. In a subsequent in vivo antitumour study, SRJ09 delayed 
quadruple tumour growth by 4 day in HCT-116 colon cancer xenografted mice 
treated with 400 mg/kg SRJ09 (q4d×3) when compared with control. In conclusion, 
SRJ09 have been proven as a lead anticancer agent given to its ability to induce in 
vitro cell cycle arrest and apoptosis and to have in vivo antitumour activity. 
Therefore, further studies in improving the anticancer properties of SRJ09 by 
chemical modification will be advantageous. 
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Sehingga kini, kebanyakan agen antikanser klinikal bertindak ke atas sel yang 
membahagi dengan cepat dan mempunyai mekanisme yang tidak selektif dengan 
mengganggu komponen asas yang penting untuk kedua-dua sel kanser dan sel 
normal. Oleh yang demikian, penemuan agen antikanser yang lebih efektif dan 
selektif kini dikaji dengan aktif dengan melibatkan pelbagai entiti program 
penemuan ubatan. Kajian kami di UPM menunjukkan bahawa andrographolide 
(AGP), sebatian yang dipencil dari Andrographis paniculata, mempunyai aktiviti 
antikanser secara in vitro and in vivo. Untuk meningkatkan potensi antitumor AGP, 
terbitan semisintetik sebatian ini disintesis di makmal kami, bertujuan untuk 
mengenalpasti sebatian antikanser yang poten di antara terbitan AGP dan seterusnya 
memahami mekanisme tindakannya. Secara in vitro, 3,19-(2-
bromobenzylidene)andrographolide (SRJ09) menunjukkan kelebihan aktiviti 
antikanser berbanding dengan AGP dan terbitan yang lain seperti 3,19-(2-
chlorobenzylidene)andrographolide (SRJ11) dan 3,19-(3-chloro-4-
fluorobenzylidene)andrographolide (SRJ23). Aktiviti antikanser AGP, SRJ09, SRJ11 
dan SRJ23 didapati tidak dipengaruhi oleh aktiviti P-glikoprotein sel MES-SA Dx5 
yang resistan terhadap pelbagai agen antikanser. Kajian berlandaskan masa 
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menunjukkan SRJ09 mempunyai sela masa tindakan yang pantas berbanding dengan 
AGP. Kajian terdahulu menunjukkan bahawa SRJ09 merencat kitaran sel pada fasa 
G1 dan dalam kajian ini, kesan ini didapati berpunca dari peningkatan ekspresi p21 
(perencat kinase bergantung siklin) dan tidak menpengaruhi ekspresi siklin D1. 
Kajian yang selanjutnya menunjukkan bahawa apoptosis merupakan punca utama 
kematian sel yang diaruh oleh SRJ09 dan adalah bebas daripada regulasi p53 dan 
Bcl-2. Untuk tujuan penentuan dos kajian in vivo, kajian farmakokinetik ringkas ke 
atas mencit Balb/c menunjukkan bahawa SRJ09 mempunyai separuh hayat yang 
pendek tetapi mampu mencapai julat konsentrasi sitotoksik in vitro. Dalam kajian in 
vivo, SRJ09 melewatkan pertumbuhan tumor kepada empat kali ganda selama empat 
hari dalam mencit yang dixenograf dengan kolon kanser HCT-116 yang dirawat 
dengan 400 mg/kg SRJ09 (q4d×3) berbanding dengan kawalan. Kesimpulannya, 
SRJ09 dikenalpasti sebagai agen antikanser pilihan utama kerana kebolehannya 
untuk merencat kitaran sel dan mengaruh apoptosis secara in vitro serta 
menunjukkan aktiviti antikanser secara in vivo. Justeru itu, kajian lanjutan untuk 
memperbaiki aktiviti antikansernya melalui modifikasi kimia adalah bermanfaat.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.3 Overview 
 
Cancer is a new growth of tissue in which cell multiplication is uncontrolled and 
progressive. Unlike benign tumour cells, cancer cells exhibit the properties of 
invasion and metastasis and are highly anaplastic. In 2002, it is reported that cancer 
is the second major cause of death, which account 12.5% of total deaths worldwide 
(The World Health Report 2003). Surgical excision, radiation therapy and 
chemotherapy are the main approaches to treat cancer. Unlike surgery and radiation 
therapy, chemotherapy is considered a systemic treatment in which the drugs 
circulate in the blood circulations to eradicate cancer micrometastases at distant sites 
from the original cancer. Therefore, chemotherapy is often administered in 
conjunction with local therapy such as surgery and radiation to obtained optimal 
effects. The use of anticancer drugs as part of the treatment strategy for cancer has 
greatly improved the overall prognosis of cancer patients.  
 
To date, most of the anticancer drugs target all rapidly dividing cells and are non-
selective in their mechanism of action by disrupting essential components or 
metabolic pathways that are crucial to both malignant and normal cells (Ewesuedo 
and Ratain 2003). Therefore, scientists are still looking for more effective and type-
selective antitumour drugs with minimum side effects. Several strategies were 
employed which include chemical modification or combinatorial chemistry involving 
 2 
existing natural and synthetic products, structure-based drug design and new natural 
products discovery. The search for new natural products from the vast biodiversity is 
an importance source of structural diversity that yield unusual and unexpected lead 
structures which served as starting points for chemical modification to derive an 
optimal drug (Young 1999). 
 
In the early 2000, andrographolide (AGP) a compound isolated from Andrographis 
paniculata received much attention as a candidate to be developed into anticancer 
agents. AGP was shown to inhibit tumour growth both in vitro and in vivo (Stanslas 
et al. 2001; Rajagopal et al. 2003).  AGP was also reported to cause G1 phase cell 
cycle arrest (Stanslas et al. 2001; Rajagopal et al. 2003) and apoptosis (Cheung et al. 
2005; Kim et al. 2005; Zhou et al. 2006). Shortly, AGP was derivatised through 
various chemical modifications in an effort to improve its antitumour potential 
(Nanduri et al. 2004; Jada et al. 2006). The derivatives synthesised by coupling of 
two hydroxyl groups in AGP (C-3 and C-19) by reacting AGP with benzaldehydes 
having different functional groups are generally shown to have an improvement in 
terms of antitumour activity (Jada et al. 2006). Hence, in this study several lead 
derivatives were selected and evaluated, in order to identify the most potent 
anticancer compound among AGP derivatives and their mechanism(s) of action.  
 
 
 
 
 
 
